Severity: Warning
Message: file_get_contents(https://...@pubfacts.com&api_key=b8daa3ad693db53b1410957c26c9a51b4908&a=1): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests
Filename: helpers/my_audit_helper.php
Line Number: 176
Backtrace:
File: /var/www/html/application/helpers/my_audit_helper.php
Line: 176
Function: file_get_contents
File: /var/www/html/application/helpers/my_audit_helper.php
Line: 250
Function: simplexml_load_file_from_url
File: /var/www/html/application/helpers/my_audit_helper.php
Line: 1034
Function: getPubMedXML
File: /var/www/html/application/helpers/my_audit_helper.php
Line: 3152
Function: GetPubMedArticleOutput_2016
File: /var/www/html/application/controllers/Detail.php
Line: 575
Function: pubMedSearch_Global
File: /var/www/html/application/controllers/Detail.php
Line: 489
Function: pubMedGetRelatedKeyword
File: /var/www/html/index.php
Line: 316
Function: require_once
Parkinson's disease (PD) is characterized by a long period of 'latent' course of the neurodegenerative process. Non-motor symptoms, including behavioral dysfunction in the REM sleep phase, hyposmia, constipation, depression, may be detected in patients before the development of movement disorders. The combination of these manifestations can be used to identify the risk group for the subsequent development of PD. These patients can be further investigated using biomarkers. Dopamine receptor agonists are the first-choice drugs at the onset of disease, providing correction of not only motor, but also non-motor symptoms.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.17116/jnevro2019119061119 | DOI Listing |
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!